Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric Jourdan

Showing results (61-70 of 83) with videos related to

Pageof 9
Sort By:
Oncotarget|February 22, 2018
SNP-array lesions in core binding factor acute myeloid leukemiaNicolas Duployez, Elise Boudry-Labis, Christophe Roumier, et al.
JAMA Oncology|July 17, 2015
Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis: A Randomized Clinical TrialAnimesh Pardanani, Claire Harrison, Jorge E Cortes, et al.
Annals of Hematology|January 25, 2024
Hypomethylating agent monotherapy in core binding factor acute myeloid leukemia: a French multicentric retrospective studyLudovic Gabellier, Pierre Peterlin, Sylvain Thepot, et al.
Blood|March 17, 2016
Comprehensive mutational profiling of core binding factor acute myeloid leukemiaNicolas Duployez, Alice Marceau-Renaut, Nicolas Boissel, et al.
Haematologica|October 19, 2010
Liposomal cytarabine is effective and tolerable in the treatment of central nervous system relapse of acute lymphoblastic leukemia and very aggressive lymphomaNicola Gökbuget, Christina-Maria Hartog, Renato Bassan, et al.
Haematologica|February 26, 2015
Dasatinib in high-risk core binding factor acute myeloid leukemia in first complete remission: a French Acute Myeloid Leukemia Intergroup trialNicolas Boissel, Aline Renneville, Thibaut Leguay, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 19, 2010
Addition of lomustine to idarubicin and cytarabine improves the outcome of elderly patients with de novo acute myeloid leukemia: a report from the GOELAMSArnaud Pigneux, Jean-Luc Harousseau, Francis Witz, et al.
European Journal of Haematology|March 18, 2021
Conventional chemotherapy for acute myeloid leukemia in older adults: Impact on nutritional, cognitive, and functional statusClaire Jouzier, Jean-François Hamel, Pierre-Yves Dumas, et al.
The New England Journal of Medicine|December 24, 2010
Imatinib plus peginterferon alfa-2a in chronic myeloid leukemiaClaude Preudhomme, Joëlle Guilhot, Franck Emmanuel Nicolini, et al.
Blood|January 17, 2013
Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemiaEric Jourdan, Nicolas Boissel, Sylvie Chevret, et al.
Pageof 9

Showing results (61-70 of 83) with videos related to

Sort By:
Pageof 9
Oncotarget|February 22, 2018
SNP-array lesions in core binding factor acute myeloid leukemiaNicolas Duployez, Elise Boudry-Labis, Christophe Roumier, et al.
JAMA Oncology|July 17, 2015
Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis: A Randomized Clinical TrialAnimesh Pardanani, Claire Harrison, Jorge E Cortes, et al.
Annals of Hematology|January 25, 2024
Hypomethylating agent monotherapy in core binding factor acute myeloid leukemia: a French multicentric retrospective studyLudovic Gabellier, Pierre Peterlin, Sylvain Thepot, et al.
Blood|March 17, 2016
Comprehensive mutational profiling of core binding factor acute myeloid leukemiaNicolas Duployez, Alice Marceau-Renaut, Nicolas Boissel, et al.
Haematologica|October 19, 2010
Liposomal cytarabine is effective and tolerable in the treatment of central nervous system relapse of acute lymphoblastic leukemia and very aggressive lymphomaNicola Gökbuget, Christina-Maria Hartog, Renato Bassan, et al.
Haematologica|February 26, 2015
Dasatinib in high-risk core binding factor acute myeloid leukemia in first complete remission: a French Acute Myeloid Leukemia Intergroup trialNicolas Boissel, Aline Renneville, Thibaut Leguay, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 19, 2010
Addition of lomustine to idarubicin and cytarabine improves the outcome of elderly patients with de novo acute myeloid leukemia: a report from the GOELAMSArnaud Pigneux, Jean-Luc Harousseau, Francis Witz, et al.
European Journal of Haematology|March 18, 2021
Conventional chemotherapy for acute myeloid leukemia in older adults: Impact on nutritional, cognitive, and functional statusClaire Jouzier, Jean-François Hamel, Pierre-Yves Dumas, et al.
The New England Journal of Medicine|December 24, 2010
Imatinib plus peginterferon alfa-2a in chronic myeloid leukemiaClaude Preudhomme, Joëlle Guilhot, Franck Emmanuel Nicolini, et al.
Blood|January 17, 2013
Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemiaEric Jourdan, Nicolas Boissel, Sylvie Chevret, et al.
Pageof 9